• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Recent advances in protein kinase inhibition: current molecular scaffolds used for inhibitor synthesis.

作者信息

Stover D R, Lydon N B, Nunes J J

机构信息

Kinetix Pharmaceuticals Inc, Medford, MA 02155, USA.

出版信息

Curr Opin Drug Discov Devel. 1999 Jul;2(4):274-85.

PMID:19649955
Abstract

Early efforts to discover and develop protein kinase inhibitors have focused largely on a small group of oncology targets such as the EGFR and PKC enzymes. More recently, hundreds of protein kinases have been identified at the genetic level, many of which are now being assigned functions in a variety of signaling pathways. Additionally, mutagenesis and X-ray crystallographic studies have further defined common structural features associated with binding of the ATP cofactor within a conserved ATP binding cleft. These studies have also demonstrated significant differences in the ATP binding cleft between individual kinases, providing a molecular basis for understanding and exploiting inhibitor specificity. The current review will focus on recent developments in the field of ATP site-directed inhibitors with particular emphasis on the major scaffolds being derivatized to take advantage of variable regions of the active site.

摘要

相似文献

1
Recent advances in protein kinase inhibition: current molecular scaffolds used for inhibitor synthesis.
Curr Opin Drug Discov Devel. 1999 Jul;2(4):274-85.
2
Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.剖析Janus激酶的特异性:与JAK1和JAK2蛋白酪氨酸激酶结构域复合的JAK特异性抑制剂的结构
J Mol Biol. 2009 Mar 20;387(1):219-32. doi: 10.1016/j.jmb.2009.01.041. Epub 2009 Jan 29.
3
3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds.3,5-二苯基戊-2-烯酸作为蛋白激酶PDK1的变构激活剂:构效关系及结合的热力学表征——作为靶向PIF结合口袋化合物的范例
J Med Chem. 2009 Aug 13;52(15):4683-93. doi: 10.1021/jm9001499.
4
Recent progress towards the identification of selective inhibitors of serine/threonine protein kinases.丝氨酸/苏氨酸蛋白激酶选择性抑制剂鉴定方面的最新进展。
Curr Opin Drug Discov Devel. 1999 Mar;2(2):96-109.
5
Development of selective bisubstrate-based inhibitors against protein kinase C (PKC) isozymes by using dynamic peptide microarrays.利用动态肽微阵列开发针对蛋白激酶C(PKC)同工酶的选择性双底物抑制剂。
Chembiochem. 2009 Aug 17;10(12):2042-51. doi: 10.1002/cbic.200900199.
6
Inorganic polyphosphate: essential for growth and survival.无机多聚磷酸盐:生长和生存所必需。
Annu Rev Biochem. 2009;78:605-47. doi: 10.1146/annurev.biochem.77.083007.093039.
7
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.新型HGF和VEGF受体酪氨酸激酶抑制剂EXEL-2880(XL880,GSK1363089)对肿瘤细胞生长、侵袭和转移的抑制作用
Cancer Res. 2009 Oct 15;69(20):8009-16. doi: 10.1158/0008-5472.CAN-08-4889. Epub 2009 Oct 6.
8
ATP site-directed kinase inhibitors.ATP位点定向激酶抑制剂。
IDrugs. 1998 May;1(1):10-2.
9
Identification of structural determinants for inhibition strength and specificity of wheat xylanase inhibitors TAXI-IA and TAXI-IIA.小麦木聚糖酶抑制剂TAXI-IA和TAXI-IIA抑制强度及特异性的结构决定因素鉴定
FEBS J. 2009 Jul;276(14):3916-27. doi: 10.1111/j.1742-4658.2009.07105.x. Epub 2009 Jun 17.
10
Relating structure to function: the role of the C2 domain in Factor VIII.结构与功能的关联:C2结构域在凝血因子VIII中的作用。
Curr Opin Drug Discov Devel. 2000 Sep;3(5):516-26.

引用本文的文献

1
The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties.西马替尼和新一代靶向治疗药物的免疫药理学潜力:具有抗肿瘤/血管生成特性的受体酪氨酸激酶调节。
Saudi Pharm J. 2012 Apr;20(2):103-23. doi: 10.1016/j.jsps.2011.09.002. Epub 2011 Sep 23.